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Abstract 
Objective: To analyze patients younger than 2 years with acute lymphoblastic leukemia, 
treated in the period between 1990 and 2010 in a state reference center.
Methods: This was a clinical-epidemiological, cross-sectional, observational, and 
descriptive study. It included patients younger than 2 years with acute lymphoblastic 
leukemia, treated in the period of 1990 to 2010 in a pediatric oncology unit of a state 
reference center, totaling 41 cases.
Results: All patients were white ethnicity, and 60.9% were females. Regarding age, 
24.38% were younger than 6 months, 17.07% were between 6 months and 1 year, and 
58.53% were older than 1 year. The age of 6 months was statistically significant for the 
outcome of death. Predominant signs and symptoms were fever, bruising, and petechiae. 
A leukocyte count > 100,000 was found in 34.14% of cases, hemoglobin count < 11 in 
95.13%, and platelet count < 100,000 in 75.61. Infiltration of central nervous system was 
present in 12.91% of patients. According to the lineage, B-cell lineage predominated 
(73%), but the T-cell line was statistically significant for death. 39% of patients had 
disease recurrence. In relation to vital status, 70.73% of the patients died; septic shock 
was the main cause.
Conclusions: Acute lymphoblastic leukemia in infants has a high mortality rate, especially 
in children under 1 year and those with T-cell derived lineage. 
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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PALAVRAS-CHAVE
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Leucemia-linfoma 
linfoblástica 
precursora de células
Leucemia linfoblástica aguda em lactentes: 20 anos de experiência
Resumo 
Objetivo: Analisar pacientes com menos de dois anos de idade com leucemia linfoblásti-
ca aguda atendidos no período de 1990 a 2010, em um centro de referência estadual.
Métodos: Estudo clínico, epidemiológico, transversal, descritivo e observacional. 
Pacientes incluídos tinham menos de dois anos de idade, com leucemia linfoblástica 
aguda, tratados no período de 1990 a 2010 na unidade de oncologia pediátrica de um 
centro de referência estadual, totalizando 41 casos.
Resultados: Todos os pacientes eram Caucasianos e 60,9% eram do sexo feminino. Com 
relação à idade, 24,38% tinham menos de seis meses, 17,07% tinham entre seis meses e 
um ano e 58,53% mais do que um ano de idade. A idade de seis meses foi estatisticamente 
significante para o desfecho de óbito. Os sinais e sintomas predominantes foram febre, 
hematomas e petéquias. Uma contagem de leucócitos superior a 100.000 foi observada 
em 34,14% dos casos; hemoglobina inferior a 11 em 95,13% e contagem de plaquetas 
inferior a 100.000, em 75,61% dos casos. Infiltração do sistema nervoso central estava 
presente em 12,91% dos pacientes. Em relação à linhagem, a linhagem B predominou 
(73%), mas a linhagem de células T foi estatisticamente significativa para o óbito. Trinta 
e nove por cento dos pacientes tiveram recorrência da doença. Em relação ao estado 
vital, 70,73% dos pacientes morreram, sendo choque séptico a principal causa.
Conclusões: leucemia linfoblástica aguda em crianças tem uma alta taxa de mortalidade, 
principalmente em crianças menores de um ano e linhagem derivada de células T.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. 
Introduction
Approximately 10% of all cancers affecting children under 
15 years correspond to those diagnosed in the first year 
of life.1 Leukemia is the second most common cancer in 
children under 1 year of age, and acute lymphoblastic 
leukemia (ALL) the most frequently observed type.2
Some possible risk factors are genetic syndromes 
(Down, Noonan, trisomy 9), high birth weight (> 3.5 kg), 
previous abortion, maternal behavior (use of antihistamine, 
metronidazole, dipyrone, estrogen, alcohol consumption, 
use of marijuana and hallucinogenic drugs, radiation, and 
exposure to insecticides and pesticides).3,4
Leukemia in children under 1 year of age has distinct 
epidemiological, clinical, and biological characteristics, 
and is associated with unfavorable factors such as 
hyperleukocytosis and central nervous system (CNS) 
infiltration.5,6 In this age range, there is a predominance of 
gene rearrangements that present as 11q23 translocation, 
leading to the coexistence of the lymphoid and myeloid 
phenotypes, known as mixed lineage leukemia (MLL) 
translocation. The presence of this type of translocation is 
associated with worse prognosis.6-8
Regarding the immunophenotype, these children’s blast 
cells have a very young precursor B-cell (CD34 + / CD 19+) 
with CD 10 negativity.9
To treat leukemia in this age range, specific protocols 
are used, which have been developed by international 
cooperative groups, as childhood leukemias do not usually 
respond to traditional treatments, showing resistance to 
drugs such as corticosteroids and asparaginase.10,11 With the 
use of therapy intensification, survival has increased, but 
so has toxicity; in the CCG-1953 protocol of the Children’s 
Cancer Group, 29% of deaths occur during induction.12
The use of allogeneic bone marrow transplantation in 
these patients is still controversial, showing no difference 
in survival when compared to chemotherapy alone.13
In spite of all the therapeutic approaches, overall survival 
remains poor. In the CCG-1953 protocol of the Children’s 
Cancer Group, overall survival at five years ranged between 
22% and 30%, while for the Interfant-99 protocol, it was 
53.8%.10,12 More recently, a group from Taiwan reported a 
survival rate of 18%.14
This study aimed to assess patients younger than 2 years 
of age with ALL, treated in the pediatric oncology unit of 
the Hospital Infantil Joana de Gusmão (HIJG) from 1990 to 
2010. 
Methods
This was a clinical-epidemiological, cross-sectional, 
observational, and descriptive study. The research protocol 
was approved by the Research Ethics Committee of the 
HIJG. The study included patients younger than 2 years 
diagnosed with ALL, treated at HIJG between January, 
1990 and December, 2010. Exclusion criteria were loss at 
follow-up, transfer to another department for treatment, 
and insufficient data in the medical record. 
ALL diagnosis was based on morphology, cytochemistry, 
and flow cytometric immunophenotyping of bone marrow 
aspirate. The treatment protocols used were those 
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of national (GBTLII-85, GBTLII-93, and GBTLII-99) and 
international cooperative groups (ALL III-85, Interfant-99, 
and ALL-IC BFM 2002). 
The variables analyzed were age at diagnosis (stratified 
age range as ≤ 6 months; 6 months < age < one year; and ≥ 
one year); gender; birth weight (greater and less than 3,500 
grams); ethnicity according to the Brazilian Institute of 
Geography and Statistics (Instituto Brasileiro de Geografia 
e Estatística – IBGE) (white, black, mixed-race, Asian, and 
Native Brazilian); origin according to Santa Catarina sub 
regions, as established by IBGE (Greater Florianópolis, 
Northern Santa Catarina, Western Santa Catarina, Uplands, 
Southern Santa Catarina, Itajaí Valley); parental contact 
with pesticides; signs and symptoms at diagnosis (fever, 
bone pain, lymphadenopathy, hepatosplenomegaly, skin 
and mucosal membrane bleeding); laboratory assessment 
at diagnosis (leukocyte, hemoglobin, and platelet counts); 
CNS involvement at diagnosis; presence and type of genetic 
alterations precursor phenotype (B or T derived); vital 
status (alive or deceased); death (immediate cause, in 
remission or not of neoplastic disease, treatment period); 
relapse (medullary, extra-medullary or combined); time of 
follow-up.15
Data were collected from the medical records and 
statistics service (serviço de arquivo médico e estatística 
- SAME) and from the hospital cancer registry of the 
HIJG. 
Statistical analysis was performed using the GraphPad 
Prism 5® software. The results were analyzed using Pearson’s 
chi-squared test with 95% level of significance, thereby 
analyzing the relationship between two variables. 
Results
The total number of patients evaluated was 41, all whites, 
of which 60.97% were females. The mean age at diagnosis 
was 12.5 months, with a median of 13 months. Regarding 
the age range at diagnosis, 24.39% were younger than 6 
months, 17.07% were older than 6 months and younger 
than 1 year, and 58.53% were older than 1 year of age. 
The mean birth weight was 3,367 g, with a median of 
3,400 g. 
History of parental contact with pesticides was described 
in 19.51% of cases. A total of 39% of cases denied history of 
contact with pesticides, and in 41.5% of the cases the data 
were not available. Signs and symptoms at the diagnosis 
are summarized in Table 1. 
As for the geographic origin, considering the sub regions 
of the state of Santa Catarina according to the IBGE, 
34.14% (n = 14) of the patients came from the Itajaí Valley, 
24.39% (n = 10) from Greater Florianópolis, 17.07% (n = 7) 
from Southern Santa Catarina, 9.75% (n = 4) from Western 
Santa Catarina, 7.32% (n = 3) from Northern Santa Catarina, 
and 7.32% (n = 3) from the Uplands. The overall mean 
follow-up time was 2 years; in surviving patients, this time 
was 4.6 years. 
CNS infiltration at diagnosis was present in 12.19% of 
patients. Three patients did not undergo CSF analysis, 
as they died before the exam. CNS infiltration, when 
compared with vital status, was not statistically significant 
(p = 0.54). Hematological alterations at diagnosis are 
detailed in Table 2. 
Cytogenetic assessment was performed in 48.78% of 
cases (n = 20). Of these, 17.07% had genetic alterations, 
including 11q23:3, chromosome trissomy 8:1, terminal 
deletion of the long arm of chromosome 7:1 and t (15, 17). 
Data were not available in 51.22% of the cases. 
In 73.17% of cases the precursor phenotype was derived 
from B-lineage, and in14.63%, from T-lineage cells. 
Regarding the vital status, 29.27% of the patients were 
alive (two patients undergoing treatment). The outcome 
of death occurred in 70.73% of patients (two patients off 
treatment and in clinical remission). Leukocyte count at 
diagnosis and its comparison with vital status are described 
in Table 3. Age at diagnosis and its association with vital 
status is described in Table 4.
Of the patients who died (n = 29), only five of them were 
in clinical remission, and three deaths occurred during 
treatment induction. The main cause of death was septic 
shock (41% of deaths). Disease relapse occurred in 39.02% 
of cases (n = 16); 12 patients presented medullary relapse, 
three presented CNS relapse, and one patient presented 
combined relapse (medullary and CNS). Only two patients 
underwent allogeneic bone marrow transplant; of these, 
one is alive and in remission. 
Table 1 Infants with acute lymphoblastic leukemia, 
according to signs and symptoms at diagnosis, as number 
(n) and percentage (%).
Signs and symptoms n %
Fever 25 60.97
Bone pain  2 4.88
Lymphadenomegaly 12 29.26
Ecchymosis/petechiae 22 53.66
Mucosal bleeding  4 9.76
Hepatomegaly  24 58.53
Splenomegaly 16 39.02
Table 2 Infants with acute lymphoblastic leukemia, 
according to hematological alterations at diagnosis, as 
number (n) and percentage (%).
Hematological alterations n %
Leukocytes < 10,000 10 24.39
10,000 < leukocytes < 50,000  12 29.27
50,000 < leukocytes < 100,000 5 12.19
Leukocytes >100,000 14 34.14
Hemoglobin < 7 14 34.14
7 < hemoglobin < 11 25 60.97
Hemoglobin > 11 2 4.87
Platelets < 20,000  2 4.87
20,000 < platelets < 100,000 29 70.73
Platelets >100,000 10 24.39
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When comparing the precursor phenotype with vital 
status, 40% of patients with B-lineage-derived cells survived 
and 60% died. All patients with T-lineage-derived cells 
died. Using the chi-squared test to compare the lines with 
vital status, a p-value = 0.0006 was obtained, and thus, 
T-lineage was statistically significant for death. There was 
no statistical significance when comparing birth weight (< 
and > 3,500 g) with vital status (p = 0.31).
Discussion
Leukemia in children younger than one year is more 
common in girls (1.17:1), a result confirmed by this study. 
In the SEER study, the white ethnicity was more affected, 
but no difference was observed regarding response to 
treatment when compared to the black ethnicity. In the 
present research, all patients were whites, consistent 
with the demographic characteristics of the state of Santa 
Catarina.1,2
Most patients came from the nearby regions, such as 
Itajaí valley and the state capital city, Florianópolis, as 
HIJG is a referral center for cancer treatment in the 
region. 
According to Naumburg, exposure to pesticides is not 
a proven risk factor for the development of leukemia; 
however, Slate et al. found an association between leukemia 
in infants and gestational exposure to petroleum-derived 
products, such as benzene. Maternal exposure to pesticides 
was verified in 19% of the patients in this study.3,4 
Leukemia in children younger than 1 year usually 
presents as hyperleukocytosis at diagnosis. Mann et al. and 
Tomizawa et al., evaluating this age range, showed that 
most patients presented more than 100,000 leukocytes 
at diagnosis, which is similar to the results found in the 
present study, where 34% had a leukocyte count > 100,000 
cells.11,16 
Pui et al. reported that CNS infiltration is more common 
in leukemia diagnosed in children younger than 1 year.6 
In the Japanese group, 20% of patients showed CNS 
infiltration; the same was observed for 9% of patients in 
the Interfant-99 group10,11 Similar to that observed in the 
Interfant-99 group, CNS infiltration in the present study 
was not statistically significant for death.10 However, 
in the study by Rives et al., evaluating T-cell-derived 
leukemia, CNS infiltration at diagnosis was significant for 
death.17 
Most patients in the present study had B-cell precursor 
phenotype. According to Ribeiro et al., T-cell-derived 
leukemias are more aggressive, a result corroborated by 
this study, where this lineage was statistically significant 
for death (p = 0.0006).18 Rives et al. achieved overall 
survival at five years of 74% in T-cell-derived leukemia, 
whereas Hunger et al. observed an overall survival of 90% 
Table 3 Infants with acute lymphoblastic leukemia, according to leukocyte count at diagnosis and vital status as number (n) 
and percentage (%).
 Alive  Dead  Total  
 n % n % n % 
Leukocyte count
< 10,000 3 7.31 7 17.07 10 24.3
≥ 10,000 < 50,000 5 12.1 7 17.07 12 9
≥ 50,000 < 100,000 2 9 3 7.31 5 29.27
≥ 100,000 2 4.87 12 29.27 14 12.19 
  4.87    34.14
Total 12 29.24 29 70.76 41 100.00
p = 0.09 (chi-squared test).
Vital 
status
Table 4 Infants with acute lymphoblastic leukemia, according to age at diagnosis and vital status as number (n) and 
percentage (%).
 Alive  Dead   Total  
 n % n % n % 
Age at diagnosis
< 6 months 1 2.43 9 21.95 10 24.3*
6 months < age < 1 year 1 2.43 6 14.63 7 17.07
> 1 year 10 24.39 14 34.14 24 58.53
Total 12 29.24 29 70.76 41 100
*p = 0.002 (Chi-squared test).
Vital 
status
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in B-cell derived leukemia, considering all age ranges of 
childhood.17,19 
Overall five-year survival rate can reach up to 90% 
in children older than 1 year, while in those younger 
than 1 year, the survival rate decreases dramatically. 
The Interfant-99 group had a survival rate of 47%; the 
Associazione Italiana Ematologia Pediatric Oncology (AIEOP 
91-95), 45%; the Berlin-Frankfurt-Munster (BFM), 43%; the 
Children’s Cancer Group (CCG) 1953, 42%; and the Taiwan 
group, 18%.5,10,14,20
This study found an overall survival of 29%. As in the 
aforementioned studies, of the patients who died, most 
were not in remission. The intensive use of chemotherapy 
in an attempt to remit the disease can cause long periods 
of severe neutropenia, exposing patients to diverse types 
of infection. In this study, the main cause of death was 
septic shock, probably due to the prolonged period of 
neutropenia. Therefore, intensification of supportive care, 
prevention, and prompt treatment of infections becomes 
an extremely important factor in the management of these 
patients.
The presence of genetic alterations as the MLL 
rearrangement is associated with a worse prognosis, and is 
more frequently observed in younger infants; according to 
Bueno, it may originate in the intrauterine period8. Genetic 
evaluation was not possible in all patients in this study; 
however, age younger than 6 months showed statistical 
significance for death, suggesting a possible correlation 
with the presence of genetic alterations.8 
Considering the poor prognosis associated with ALL 
in children younger than 1 year, it is important to 
develop new therapeutic strategies. In this context, 
the literature describes new treatments, such as trans-
retinoic acid, vitamin D3, histone deacetylase, and 
DNA-methyltransferase-inhibitors, which could improve 
clinical outcomes in patients younger than one year 
with leukemia.11,16 However, more studies are needed to 
demonstrate the efficacy of these agents. 
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